UNC's Update on Biomarkers in Targeted Therapy for Advanced NSCLC: Did FDA-Approved Capmatinib Demonstrate Antitumor Activity in Patients With MET Exon 14 Skipping Mutations?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

UNC's Update on Biomarkers in Targeted Therapy for Advanced NSCLC: Did FDA-Approved Capmatinib Demonstrate Antitumor Activity in Patients With MET Exon 14 Skipping Mutations?

By UNC Lineberger Comprehensive Cancer Center FEATURING Shetal Patel

82 views

March 18, 2021

0 Comments

Vogl,NY on How to Ask Good Questions at Medical Meetings

Feat. S. Vogl

35:40

Balazs Halmos

Year in Review: Lung Cancer

27:04

Fengting Yan

Cancer Screening Molecular Tools

25:35

Total Health

NGS and Liquid Biopsy: Overcoming Challenges in Widespread Testing

Feat. S. Kazmi

13:19

IASLC Targeted Therapies of Lung Cancer 2023 Conference Coverage

Duration of Immunotherapy Beyond 2 Years for Patients With Advanced …

Feat. E. Rodriguez

07:43

Yale Cancer Center

2024 Updates on NSCLC Targeted Therapies: FLAURA2 Trial - Osimertini…

Feat. P. Janne

06:47

UCSF School of Medicine

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+…

Feat. H. Kang

20:52

Total Health

Diagnostics in Lung Cancer: A Comprehensive Discussion - Best of Lun…

Feat. T. Boyle

08:49

David Carbone

The Use of IO Doublet in PD-L1-Negative NSCLC

26:21

Memorial Sloan Kettering Cancer Center

NSCLC & Targeted Therapy: A Brief Overview and Update in the Met…

Feat. M. Hwang

14:49

Vivek Subbiah

Year in Review: Precision Medicine

05:02

GRACE

Targeted Therapies in Lung Cancer 2023: Biomarkers in NSCLC

Feat. A. Desai

23:32

2023 West Oncology Conference

2023 Updates on Neoadjuvant and Adjuvant NSCLC

Feat. M. Johnson

16:12

Total Health

2024 Updates on the Fast-Changing NSCLC Landscape

Feat. R. Osarogiagbon

11:50

GRACE

The CheckMate 816 Trial: The Success of Neoadjuvant NSCLC Therapies

Feat. J. Rotow

22:57

Total Health

Lung Cancer Screening - Best of Lung 2023

Feat. C. Olazagasti

54:26

Yale Cancer Center

Year in Review: Progress in NSCLC Treatment

Feat. R. Herbst

07:27

Jason Levy

Opus One: Final Results - RFA in Axial Skeleton

08:30

Insights from 2023 ESMO Annual Meeting

PAPILLON Study - Amivantamab + Chemo vs. Chemo as 1L Treatment in EG…

Feat. N. Girard

20:27

Yale Cancer Center

Progress in the Treatment of NSCLC

Feat. R. Herbst

Login

Login

Join VuMedi

UNC's Update on Biomarkers in Targeted Therapy for Advanced NSCLC: Did FDA-Approved Capmatinib Demonstrate Antitumor Activity in Patients With MET Exon 14 Skipping Mutations?

Related Content